Thomas P. Burris

17.6k total citations · 3 hit papers
190 papers, 13.4k citations indexed

About

Thomas P. Burris is a scholar working on Molecular Biology, Genetics and Surgery. According to data from OpenAlex, Thomas P. Burris has authored 190 papers receiving a total of 13.4k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Molecular Biology, 55 papers in Genetics and 40 papers in Surgery. Recurrent topics in Thomas P. Burris's work include Estrogen and related hormone effects (48 papers), Cholesterol and Lipid Metabolism (37 papers) and Retinoids in leukemia and cellular processes (29 papers). Thomas P. Burris is often cited by papers focused on Estrogen and related hormone effects (48 papers), Cholesterol and Lipid Metabolism (37 papers) and Retinoids in leukemia and cellular processes (29 papers). Thomas P. Burris collaborates with scholars based in United States, Egypt and Spain. Thomas P. Burris's co-authors include Douglas J. Kojetin, Laura A. Solt, Kelli Bramlett, Theodore M. Kamenecka, Patrick R. Griffin, Rajesh S. Savkur, Keith R. Stayrook, Christine Crumbley, Edward R.B. McCabe and Kristine Griffett and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Thomas P. Burris

187 papers receiving 13.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists

2012 649 citations Laura A. Solt, Yongjun Wang et al. profile →
Structure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNA

2008 626 citations Thomas P. Burris et al. profile →
REV-ERB and ROR nuclear receptors as drug targets

2014 415 citations Douglas J. Kojetin, Thomas P. Burris profile →

Peers

Countries citing papers authored by Thomas P. Burris

Since Specialization

Citations

This map shows the geographic impact of Thomas P. Burris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas P. Burris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas P. Burris more than expected).

Fields of papers citing papers by Thomas P. Burris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas P. Burris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas P. Burris. The network helps show where Thomas P. Burris may publish in the future.

Co-authorship network of co-authors of Thomas P. Burris

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas P. Burris. A scholar is included among the top collaborators of Thomas P. Burris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas P. Burris. Thomas P. Burris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	REV-ERBα regulates brain NAD+ levels and tauopathy via an NFIL3–CD38 axis 2025 ·Nature Aging ·(unknown), (unknown), (unknown), (unknown), (unknown), Jaymie R. Voorhees, Julie Dimitry, (unknown), Lauren N. Woodie, Brian V. Lananna, Li Gan, Yong Sook Goo, Guoyan Zhao, Mitchell A. Lazar, Thomas P. Burris, Erik S. Musiek	0
2	Merging Natural Product Structures with Pharmaceutical Leads: Unnatural Enantiomers of Estranes as Glucocorticoid Receptor Modulators That Suppress TNF-α and IL-6 Release 2024 ·Journal of Medicinal Chemistry ·(unknown), Dexi Yang, (unknown), (unknown), Christopher C. Coss, Thomas P. Burris, Xiao Hu, Glenn C. Micalizio	1
3	Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915 2023 ·European Journal of Medicinal Chemistry ·(unknown), Sadichha Sitaula, Cyrielle Billon, (unknown), (unknown), (unknown), (unknown), Arindam Chatterjee, Kristine Griffett, Subhashis Banerjee, (unknown), (unknown), (unknown), (unknown), Ian Mitchelle S. de Vera, Thomas P. Burris, John K. Walker	4
4	REV-ERB is essential in cardiac fibroblasts homeostasis 2022 ·Frontiers in Pharmacology ·(unknown), Shiyang Song, Lei Qi, (unknown), Hui Li, Weiyi Xu, (unknown), Thomas P. Burris, (unknown), Zheng Sun, Lilei Zhang	8
5	A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis 2021 ·PLoS ONE ·(unknown), (unknown), (unknown), (unknown), Arindam Chatterjee, Kristine Griffett, Thomas P. Burris, Colin A. Flaveny	9
6	Naturally Occurring Genetic Variants in the Oxytocin Receptor Alter Receptor Signaling Profiles 2021 ·ACS Pharmacology & Translational Science ·Manasi Malik, Michael D. Ward, (unknown), Justin R. Porter, Maxwell I. Zimmerman, (unknown), Michelle E. Roh, Antonina I. Frolova, Thomas P. Burris, Gregory R. Bowman, P. I. Imoukhuede, Sarah K. England	7
7	Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy 2020 ·Cancer Immunology Research ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Kristine Griffett, Thomas P. Burris, Kelly D. Pyles, (unknown), Mary L. Preuss, Kevin A. Bockerstett, Maureen J. Donlin, Kyle S. McCommis, Richard J. DiPaolo, Ryan M. Teague	29
8	Rev-erbα heterozygosity produces a dose-dependent phenotypic advantage in mice 2020 ·PLoS ONE ·Ryan D. Welch, Cyrielle Billon, (unknown), Thomas P. Burris, Colin A. Flaveny	5
9	Rev-Erb co-regulates muscle regeneration via tethered interaction with the NF-Y cistrome 2017 ·Molecular Metabolism ·Ryan D. Welch, Chun Guo, (unknown), Katherine J. Carpenter, Natalie Stephens, (unknown), Marvin J. Meyers, Lauren M. Sparks, Steven R. Smith, Jinsong Zhang, Thomas P. Burris, Colin A. Flaveny	22
10	Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle 2017 ·Scientific Reports ·Ryan D. Welch, Cyrielle Billon, (unknown), Thomas P. Burris, Colin A. Flaveny	31
11	Rev-erb regulation of cholesterologenesis 2017 ·Biochemical Pharmacology ·Sadichha Sitaula, Jinsong Zhang, (unknown), Thomas P. Burris	24
12	Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression 2016 ·PLoS ONE ·Ariadna Amador, Yongjun Wang, Subhashis Banerjee, (unknown), Laura A. Solt, Thomas P. Burris	24
13	Artemisia extracts activate PPARγ, promote adipogenesis, and enhance insulin sensitivity in adipose tissue of obese mice 2014 ·Nutrition ·Allison J. Richard, Thomas P. Burris, David Sánchez‐Infantes, Yongjun Wang, David Ribnicky, Jacqueline M. Stephens	29
14	Small molecule tertiary amines as agonists of the nuclear hormone receptor Rev-erbα 2012 ·Bioorganic & Medicinal Chemistry Letters ·Youseung Shin, Romain Noël, Subhashis Banerjee, Douglas J. Kojetin, Xinyi Song, Yuanjun He, Lin Li, Michael D. Cameron, Thomas P. Burris, Theodore M. Kamenecka	17
15	Liver X Receptor-Retinoid X Receptor (LXR-RXR) Heterodimer Cistrome Reveals Coordination of LXR and AP1 Signaling in Keratinocytes 2011 ·Journal of Biological Chemistry ·Qi Shen, Yuchen Bai, Ken C. N. Chang, Yongjun Wang, Thomas P. Burris, Leonard P. Freedman, Catherine C. Thompson, Sunil Nagpal	43
16	The Benzenesulfoamide T0901317 [N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] Is a Novel Retinoic Acid Receptor-Related Orphan Receptor-α/γ Inverse Agonist 2009 ·Molecular Pharmacology ·Naresh Kumar, Laura A. Solt, Juliana J. Conkright, Yongjun Wang, Monica A. Istrate, Scott A. Busby, Rubén D. Garcia-Ordoñez, Thomas P. Burris, Patrick R. Griffin	196
17	Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method 2008 ·Proceedings of the National Academy of Sciences ·Susie Y. Dai, Michael J. Chalmers, John B. Bruning, Kelli Bramlett, Harold E. Osborne, Chahrzad Montrose‐Rafizadeh, Robert J. Barr, Yong Wang, Minmin Wang, Thomas P. Burris, Jeffrey A. Dodge, Patrick R. Griffin	68
18	Relationship between circadian oscillations of Rev-erbα expression and intracellular levels of its ligand, heme 2008 ·Biochemical and Biophysical Research Communications ·Pamela M. Rogers, (unknown), Thomas P. Burris	46
19	Thioether side chain cyclization for helical peptide formation: inhibitors of estrogen receptor–coactivator interactions 2004 ·Journal of Peptide Research ·Amit K. Galande, (unknown), Thomas P. Burris, James L. Wittliff, Arno F. Spatola	54
20	Nuclear receptors and genetic disease 2001 ·Academic Press eBooks ·Thomas P. Burris, Edward R.B. McCabe	98

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact